Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
08:00am, Monday, 29'th Dec 2025
BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-C
Tiziana Life Sciences begins dosing in Phase 2 Alzheimer's trial - ICYMI
11:09am, Saturday, 20'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about a series of important developments for the company, including the dosing of its first patient in an early Alzheimer
Tiziana Life Sciences begins dosing in Phase 2 Alzheimer’s trial - ICYMI
06:00am, Saturday, 20'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about a series of important developments for the company, including the dosing...
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
11:00am, Friday, 19'th Dec 2025
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies w
Tiziana Life Sciences executive chairman increases stake
06:29am, Friday, 19'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA), a biotechnology firm developing immunomodulation therapies, including intranasal foralumab, said its executive...
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
10:00am, Wednesday, 17'th Dec 2025
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies w
Tiziana Life Sciences doses first patient in mid-stage Alzheimer's trial
09:08am, Wednesday, 17'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Wednesday it has dosed the first patient in a Phase 2 clinical trial testing its intranasal drug candidate foralumab in patients with early Alzheimer's
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial
08:45am, Wednesday, 17'th Dec 2025
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
03:07pm, Monday, 15'th Dec 2025
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana CEO boosts stake with open-market share purchase
10:21am, Monday, 15'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its Chief Executive Officer Ivor Elrifi has bought 163,400 shares of the biotechnology company’s common stock...
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering
07:30am, Monday, 15'th Dec 2025
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences withdraws proposed share offering
05:34am, Monday, 15'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has withdrawn its proposed public offering of common shares, citing market conditions. The company, focused on...
Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer's trial next week
03:31pm, Friday, 12'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has begun enrolling participants in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in early Alzheim
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial
02:10pm, Friday, 12'th Dec 2025
BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer’s trial next week
10:27am, Friday, 12'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has begun enrolling participants in its Phase 2 randomized, placebo-controlled clinical trial...
